The Molecular Oncology (MO) Program at Georgetown Lombardi Comprehensive Cancer Center brings together investigators whose mission is to identify and validate molecular pathways critical to the initiation, progression, maintenance and metastases of cancer.
MO specifically investigates those aspects of cancer that clearly differentiate cancer from non-cancer cells. The goal is to validate targets, identify the most critical pathways and create novel probes that will lead to a transition for clinical trials with either established or novel agents.
Key accomplishments in this Program include the discovery of a novel small molecule that targets an oncogenic fusion protein, the finding of STAG2 as a regulator of chromosomal integrity that is deleted in many cancers, and a novel method to chemically reprogram cancer cells.
The Program has 18 full members and 23 associate members. MO has assembled an outstanding group of investigators who approach the most fundamental aspects of biology, but do so through the lens of cancer models.
This Program was developed to address three interconnected themes:
Theme 1: Unique genomic events that initiate and sustain cancer growth;
Theme 2: The immortal lives of cancer cells;
Theme 3: Metastatic mechanisms that allow the spread of cancer.
- Chris Albanese, PhD
- Maria Laura Avantaggiati, MD
- Stephen W. Byers, PhD
- Fung-Lung Chung, PhD
- Karen Creswell, PhD
- Albert J. Fornace, MD
- Eric Glasgow, PhD
- Cecil Han, PhD
- Joanna Kitlinska, PhD
- Jan LaRocque, PhD
- Dean Rosenthal, PhD
- Rabindra Roy, PhD
- Richard C. Schlegel, MD, PhD
- Jeffrey Toretsky, MD (Program Leader)
- Benjamin Tycko, MD, PhD (Program Leader)
- Aykut Uren, MD
- Todd Waldman, MD, PhD
- Chungling Yi, PhD